DAIICHI SANKYO COMPANY, LIMITED

Top Management Presentation
Results for Q2 FY2015 (April 1 – September 30, 2015)

November 2, 2015

S
M
L

Top Management Presentation
Results for Q2 FY2015 (April 1 – September 30, 2015)

DAIICHI SANKYO COMPANY, LIMITED: Joji Nakayama
President and CEO

Mary Jane Helenek
President & CEO, Luitpold Pharmaceuticals, Inc.

1/61

from the beginning

Top Management Presentation Results for Q2 FY2015 (April 1 September 30, 2015)

Today’s Topics

FY2015 Q2 YTD Results

Overview of FY2015 Q2 YTD Results

Operating Profit

Profit attributable to owners of the Company

Major business units

Major products in Japan

FY2015 revised consolidated forecast

FY2015 revised consolidated forecast

Major management topics ・Edoxaban business update

Edoxaban business update：Japan (Lixiana)

Edoxaban business update： US (Savaysa)

Edoxaban business update： EU (Lixiana)

Edoxaban business update： other regions

Edoxaban business update: LCM others

Major management topics・Transformation of Daiichi Sankyo, Inc.

DSI: Shift in product portfolio

Transform DSI (U.S.) to a specialist-driven company

Major management topics・R&D update

Major management topics

Progress of Major R&D pipeline

Progress of Major R&D pipeline

DS-originated ADC clinical entering

Portfolio enhancement in thrombosis franchise

In-licensing flu vaccine of new value-added formulation

Major R&D pipeline

DS R&D Day 2015

Luitpold Business Update

Luitpold Pharmaceuticals, Inc. (LPI)

LPI - A Diversified Specialty Company

LPI - A Diversified Specialty Company

What Is Iron Deficiency Anemia (IDA)?

Cause of IDA*

IDA population & Treatment Options are Growing

Real Challenges in Current Iron Therapies

VenoferR: The IV iron Market Share Leader

InjectaferR: High-dose IV Iron with Broad Indication

Comparison between InjectaferR and Venofer R

Injectafer: The Fastest Growing IV Iron in US

Hem-Onc Treats most Non-Dialysis IDA patients

Growth Strategy for Injectafer

LPI - A Diversified Specialty Company

US Generic Injectable Business

LPI’s Generic Injectable Business

Growth Strategy for Generic Injectable Business

Investment to Expand Manufacturing Capacity

LPI is Positioned for Accelerated Growth

Q&A Session

Q&A 1

Q&A 2

Q&A 3

Q&A 4

Q&A 5

Q&A 6

Q&A 7

Q&A 8

Q&A 9

Q&A 10

Top Management Presentation/ Financial Results (FY2014)(PDF 2.1 MB)